Maryland Senate and House / 2026 Regular Session

HB0417: Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

In the Senate - Special Order until next session (Senator Love) Adopted

Establishing medetomidine and xylazine as Schedule III controlled dangerous substances under the Maryland Controlled Dangerous Substances Act

Official bill page · Source: Maryland General Assembly

Ask about HB0417

Legislative actions

No action history has been imported for this bill. This does not mean the bill had no actions.

Raw source record
{
    "Title": "Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine",
    "Status": "In the Senate - Special Order until next session (Senator Love) Adopted ",
    "BillType": "Regular",
    "Sponsors": [
        {
            "Name": "Delegate Pippy"
        },
        {
            "Name": "Delegate Kerr"
        },
        {
            "Name": "Delegate Alston"
        },
        {
            "Name": "Delegate Bagnall"
        },
        {
            "Name": "Delegate Cullison"
        },
        {
            "Name": "Delegate Guzzone"
        },
        {
            "Name": "Delegate Hill"
        },
        {
            "Name": "Delegate Hutchinson"
        },
        {
            "Name": "Delegate Johnson, S."
        },
        {
            "Name": "Delegate Kaufman"
        },
        {
            "Name": "Delegate Kipke"
        },
        {
            "Name": "Delegate Lopez"
        },
        {
            "Name": "Delegate Martinez"
        },
        {
            "Name": "Delegate Morgan, M."
        },
        {
            "Name": "Delegate Reilly"
        },
        {
            "Name": "Delegate Rosenberg"
        },
        {
            "Name": "Delegate Ross"
        },
        {
            "Name": "Delegate Szeliga"
        },
        {
            "Name": "Delegate Taveras"
        },
        {
            "Name": "Delegate White Holland"
        },
        {
            "Name": "Delegate Woorman"
        }
    ],
    "Statutes": [
        {
            "Article": {
                "Code": "gcr",
                "Title": "Criminal Law"
            },
            "Sections": [
                {
                    "Section": "5-404"
                }
            ]
        }
    ],
    "Synopsis": "Establishing medetomidine and xylazine as Schedule III controlled dangerous substances under the Maryland Controlled Dangerous Substances Act",
    "BillNumber": "HB0417",
    "BillVersion": "T",
    "PassedByMGA": false,
    "BroadSubjects": [
        {
            "Code": "e1",
            "Name": "Criminal Law - Substantive Crimes"
        }
    ],
    "ChapterNumber": "",
    "EmergencyBill": false,
    "NarrowSubjects": [
        {
            "Code": "age",
            "Name": "Age -see also- Age of Maj; Children; Elderly; Inf&Tod.; etc"
        },
        {
            "Code": "classid",
            "Name": "Classifications and Designations"
        },
        {
            "Code": "comptroller",
            "Name": "Comptroller"
        },
        {
            "Code": "consump",
            "Name": "Consumer Protection"
        },
        {
            "Code": "controds",
            "Name": "Controlled Dangerous Substances -see also- Drugs; Opioids"
        },
        {
            "Code": "drugs",
            "Name": "Drugs -see also- Cannabis; ControlDangSubst; Pharm; etc."
        },
        {
            "Code": "health",
            "Name": "Health -see also- COVID19; EnvHlth; MedCon; etc."
        },
        {
            "Code": "healthd",
            "Name": "Health, Department of"
        },
        {
            "Code": "identificatio",
            "Name": "Identification -see also- Biometrics; Fingerprinting; DrLics"
        },
        {
            "Code": "penalts",
            "Name": "Penalties and Sentences -see also- Death Penalty"
        },
        {
            "Code": "records",
            "Name": "Records -see also- Land Records; Vital Records"
        },
        {
            "Code": "retails",
            "Name": "Retail Sales"
        },
        {
            "Code": "revenut",
            "Name": "Revenue and Taxes -see also- (specific tax)"
        },
        {
            "Code": "rulesr",
            "Name": "Rules and Regulations"
        },
        {
            "Code": "scientr",
            "Name": "Scientific Research -see also- ChemTst; MedRsrch; Studies"
        },
        {
            "Code": "substaa",
            "Name": "Substance Abuse"
        },
        {
            "Code": "veterinarians",
            "Name": "Veterinarians"
        },
        {
            "Code": "wholesd",
            "Name": "Wholesale Distribution"
        }
    ],
    "SponsorPrimary": "Delegate Pippy",
    "YearAndSession": "2026 Regular Session",
    "StatusCurrentAsOf": "2026-11-13T11:57:19.330",
    "CrossfileBillNumber": "SB0435",
    "CommitteePrimaryOrigin": "Health",
    "ConstitutionalAmendment": false,
    "ReportDateHouseOfOrigin": "2026-03-03",
    "ReportDateOppositeHouse": "2026-04-13",
    "CommitteePrimaryOpposite": "Finance",
    "CommitteeSecondaryOrigin": "",
    "ReportActionHouseOfOrigin": "Favorable with Amendments",
    "ReportActionOppositeHouse": "Favorable",
    "CommitteeSecondaryOpposite": "",
    "InteractionBetweenChambers": "",
    "FirstReadingDateHouseOfOrigin": "2026-01-22",
    "FirstReadingDateOppositeHouse": "2026-02-22",
    "ThirdReadingDateHouseOfOrigin": "2026-02-23",
    "ThirdReadingDateOppositeHouse": null,
    "SecondReadingDateHouseOfOrigin": "2026-02-22",
    "SecondReadingDateOppositeHouse": null,
    "ThirdReadingActionHouseOfOrigin": "Passed",
    "ThirdReadingActionOppositeHouse": "",
    "SecondReadingActionHouseOfOrigin": "Passed with Amendments",
    "SecondReadingActionOppositeHouse": "",
    "HearingDateTimePrimaryHouseOfOrigin": "2026-02-10T14:30:00",
    "HearingDateTimePrimaryOppositeHouse": null,
    "HearingDateTimeSecondaryHouseOfOrigin": null,
    "HearingDateTimeSecondaryOppositeHouse": null
}